A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma

American Journal of Medicine

Volumn 111, Issue 3, 2001, Pages 195-202

  Nathan, Robert A ^a   Bleecker, Eugene R ^b   Kalberg, Chris ^c  

^a Asthma & Allergy Associates PC and Research Center   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; SALBUTAMOL; ZAFIRLUKAST;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 0035880958     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00800-2     Document Type: Article

References (38)

1. Inhaled steroids and the risk of hospitalization for asthma
2. Low-dose inhaled corticosteroids, and the prevention of death from asthma
3. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients
4. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life
5. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma
6. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
7. Effect of early versus late intervention with inhaled corticosteroids in asthma
8. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo-controlled study
9. Effects of inhaled corticosteroids on the consequences of asthma
10. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids
11. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
12. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the HPA axis
13. Comparison of fluticasone propionate with flunisolide in patients with mild-to-moderate asthma
14. The effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the HPA axis in adult asthmatics
15. Differential effects of inhaled corticosteroids: Fluticasone propionate versus triamcinolone acetonide
16. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma
17. Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma
18. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma
19. The emerging role of leukotriene antagonists in asthma therapy
20. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
21. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
22. Effects of 13 weeks of treatment with ICI 204,219 (Accolate) or cromolyn sodium (Intal) in patients with mild-to-moderate asthma
23. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
24. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma
25. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
26. Reference spirometric values using techniques and equipment that meet ATS recommendations
27. Montelukast added to inhaled beclomethasone in treatment of asthma
28. Fluticasone propionate versus zafirlukast: Effect in patients previously receiving inhaled corticosteroid therapy
29. Effect of an inhaled corticosteroid on airway inflammation and symptoms of asthma
30. Effect of inhaled beclomethasone diproprionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium or patients with mild asthma
31. Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils
32. Glucocorticoids inhibit leukotriene production
33. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
34. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial
35. Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild-to-moderate asthma